With 0.63 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.99 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.135 whereas the lowest price it dropped to was $4.87. The 52-week range on IMTX shows that it touched its highest point at $13.77 and its lowest point at $4.06 during that stretch. It currently has a 1-year price target of $17.34. Beta for the stock currently stands at 0.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IMTX was up-trending over the past week, with a rise of 14.83%, but this was up by 1.19% over a month. Three-month performance dropped to -31.04% while six-month performance fell -59.70%. The stock lost -57.42% in the past year, while it has lost -28.13% so far this year. A look at the trailing 12-month EPS for IMTX yields -0.65 with Next year EPS estimates of -0.90. For the next quarter, that number is -0.20. This implies an EPS growth rate of 38.33% for this year and -11.49% for next year.
Float and Shares Shorts:
At present, 103.11 million IMTX shares are outstanding with a float of 87.13 million shares on hand for trading. On 2025-02-28, short shares totaled 8.65 million, which was 711.00004 higher than short shares on 1738281600. In addition to Dr. Harpreet Singh Ph.D. as the firm’s CEO, MD, Member of Management Board & Executive Director, Dr. Toni Weinschenk Ph.D. serves as its Co-Founder & Chief Innovation Officer.
Institutional Ownership:
Through their ownership of 0.87514997 of IMTX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, IMTX reported revenue of $50559000.0 and operating income of $514000.0. The EBITDA in the recently reported quarter was $9073000.0 and diluted EPS was -$0.11.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With IMTX analysts setting a high price target of 20.0 and a low target of 13.0, the average target price over the next 12 months is 16.41667. Based on these targets, IMTX could surge 291.39% to reach the target high and rise by 154.4% to reach the target low. Reaching the average price target will result in a growth of 221.27% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.44817 being high and -$0.87877 being low. For IMTX, this leads to a yearly average estimate of -$0.63271. Based on analyst estimates, the high estimate for the next quarter is -$0.21 and the low estimate is -$0.23. The average estimate for the next quarter is thus -$0.22.
